The blood test may be included in the standard urologic armamentarium for biopsy decisions, risk stratification, and treatment selection for suspected prostate cancer
Redcliffe Labs has expanded its services with the addition of Prostate Health Index (PHI) test processing at its National Reference Laboratory located in Noida.
The blood test may be included in the standard urologic armamentarium for biopsy decisions, risk stratification, and treatment selection for suspected prostate cancer.
The PHI test is a simple and cost-effective blood test that plays a crucial role in identifying patients who genuinely require a prostate biopsy, ultimately reducing the occurrence of negative biopsies. It combines serum total PSA, free PSA (fPSA), and p2PSA ([-2]proPSA) concentrations through a mathematical formula that enhances clinical sensitivity and specificity for prostate cancer risk assessment. This test will benefit men aged 50 and above with non-suspicious digital rectal examination (DRE) results and a total prostate-specific antigen (PSA) range of 4 to 10 ng/mL.
Redcliffe Labs will provide same-day results for PHI tests.
Dr Sohini Sengupta, Medical Laboratory Director at Redcliffe Labs, highlights the urgency of addressing the increasing prostate cancer cases in India. To combat this challenge, Redcliffe Labs introduces the advanced PHI test, surpassing the PSA test in accuracy up to three times. This advanced test not only enhances healthcare accuracy but also empowers individuals and clinicians for informed decision-making.
- Advertisement -